Valproate plus Aripiprazole Use for Bipolar Depression
Valproate (Depakote/divalproex) is indicated for bipolar manic episodes, not bipolar depression. [1] Aripiprazole (Abilify) is indicated for bipolar manic and mixed episodes (as monotherapy and as adjunctive therapy with lithium or valproate), not bipolar depression. [2] Therefore, use of valproate combined with aripiprazole for bipolar depression does not align with labeled indications for either agent. [1][2]
FDA-Label Dosing for Aripiprazole With Valproate (Bipolar Mania/Mixed)
Aripiprazole dosing for bipolar I disorder acute treatment is described for manic and mixed episodes, including adjunctive use with valproate. [2]
- Adjunctive therapy (with lithium or valproate) for adults (acute manic or mixed episodes):
- Starting dose: 10 mg to 15 mg once daily. [2]
- Target dose: 15 mg/day. [2]
- Dose increase: may increase to 30 mg/day based on clinical response. [2]
- Dose limit: safety above 30 mg/day has not been evaluated in clinical trials. [2]
FDA-Label Dosing for Valproate (Depakote) for Bipolar Mania
Depakote dosing for bipolar manic episodes is described in the mania section of labeling. [1]
- Initial dose (mania): 750 mg daily in divided doses. [1]
- Titration: dose should be increased as rapidly as possible to achieve the lowest therapeutic dose producing the desired clinical effect or targeted plasma concentrations. [1]
- Plasma concentration target used in acute mania trials: trough plasma concentration 50 to 125 mcg/mL. [1]
- Maximum recommended dosage: 60 mg/kg/day. [1]
Practical Inpatient Application of the Labeled Combination Regimen (When Treating Mania/Mixed)
When treating bipolar I disorder manic or mixed episodes where the combination is being considered, the labeled regimen corresponds to:
- Aripiprazole: start 10–15 mg once daily, target 15 mg/day, titrate up to 30 mg/day based on response, with labeled safety limits. [2]
- Valproate (divalproex): start 750 mg/day in divided doses, titrate toward the acute mania trough plasma target range 50–125 mcg/mL, with a labeled maximum of 60 mg/kg/day. [1]
Key Safety Considerations When Co-Administered
Adjunctive aripiprazole with lithium or valproate for bipolar mania is associated with higher rates of certain adverse effects compared with placebo plus lithium or valproate in trials, including akathisia, tremor, and extrapyramidal disorder. [2]
- Akathisia: 19% with aripiprazole + lithium/valproate vs 5% with placebo + lithium/valproate. [2]
- Tremor: 9% vs 6%. [2]
- Extrapyramidal disorder: 5% vs 1%. [2]
Clinical Bottom Line for Bipolar Depression
For bipolar depression, valproate and aripiprazole lack labeled indications, and labeled dosing should not be used as a bipolar depression regimen without an evidence-based indication supporting off-label treatment selection. [1][2]